Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6321714 | 0.86 | LMNA (0.41) | LMNATSHRMAPTLCKGAA | |
| SCHEMBL7124274 | 0.85 | HTT (0.43) | TSHRMAPTGAAALDH1A1KMT2A | |
| SCHEMBL7128957 | 0.85 | ALDH1A1 (0.34) | LMNAMAPTALDH1A1KMT2AHTT | |
| SCHEMBL4405167 | 0.77 | HRH4 (0.42) | LMNATSHRMAPTGAAFGFR1 | |
| SCHEMBL6090264 | 0.77 | PDGFRB (0.41) | LMNAMAPTGAAPDGFRBFGFR1 | |
| SCHEMBL6220089 | 0.75 | SPR (0.41) | LMNAMAPTALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL5401557 | 0.74 | KDM4E (0.44) | MAPTLCKGAAPDGFRBFGFR1 | |
| SCHEMBL7126911 | 0.74 | PDGFRB (0.42) | MAPTPDGFRBFGFR1KDRALDH1A1 | |
| SCHEMBL6220131 | 0.72 | MEN1 (0.46) | LMNATSHRGAAALDH1A1KMT2A | |
| SCHEMBL5401668 | 0.70 | L3MBTL1 (0.45) | TSHRGAAPDGFRBFGFR1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6599902-B2 | For treating or preventing a protein kinase related disorder | SUGEN, INC. | 2003-07-29 | — | — | US | disclosed |
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. | 2003-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125370-A1 | 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | DMPK, ADK, MAP3K20 | LMNA 2232/4885TSHR 3115/4885MAPT 3167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.